BrainStorm Receives Notice of Intention to Grant Additional EU patent for NurOwn®

NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office (EPO) has communicated its intention to grant a European patent titled ‘Methods of Generating Mesenchymal Stem Cells which secrete Neurotrophic Factors’. Allowed claims cover the method for manufacturing MSC-NTF cells (NurOwn®).

“We continue to protect our technology through strategic intellectual property achievements and the intention to grant this patent by the European Patent Office is a welcome addition to our IP portfolio. This patent covers the industrial manufacturing process for NurOwn® developed by Brainstorm’s scientists,” commented Brainstorm’s CEO Chaim Lebovits. “Adding this EU patent to our patents granted in the United States, Canada, Israel and Japan, should increase our ability to enter into new commercial partnerships for NurOwn in the EU and worldwide.”

more at: